EVOXU — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-05-12

• For the three months ended March 31, 2026, we had net income of $1,951,845, which consisted of interest earned on investments held in Trust Account of $ 2,120,916, partially offset by operating costs of $169,071.

• On November 12, 2025, the Company consummated the Initial Public Offering of 24,000,000 Units, which includes the full exercise by the underwriters of their over-allotment option in the amount of 3,000,000 Units, at $10.00 per Unit, generating gross proceeds of $240,000,000. Simultaneously with the …

• Following the Initial Public Offering, the full exercise of the over-allotment option, and the sale of the Private Units, a total of $240,000,000 was placed in the Trust Account. We incurred transaction costs of $15,036,813, consisting of $4,320,000 of cash underwriting fee (net of $480,000 underwri…

• For the three months ended March 31, 2026, cash used in operating activities was $109,835. Net income of $1,951,845 was affected by interest earned on investments held in the Trust Account of $2,120,916. Changes in operating assets and liabilities used $59,236 of cash for operating activities.

• As of March 31, 2026, we had investments held in the Trust Account of $243,327,660 (including $3,327,660 of interest income) consisting of U.S. Treasury Bills with a maturity of 185 days or less. We may withdraw interest from the Trust Account to pay taxes, if any. We intend to use substantially all…

Text removed vs the prior filing · source: 10-Q · 2025-12-16

• For the three months ended September 30, 2025 and for the period from June 26, 2025 (inception) through September 30, 2025, we had a net loss of $72,700 and $93,518, respectively, which consisted of general and administrative costs.

• Until the consummation of the initial public offering, our only source of liquidity was an initial purchase of shares of Class B ordinary shares, par value $0.0001 per share (the “Founder Shares”), by the Sponsor, and loans from the Sponsor, which were repaid at the closing of the initial public off…

• Subsequent to the period covered by this Quarterly Report, on November 12, 2025, the Company consummated the Initial Public Offering of 24,000,000 Units, which includes the full exercise by the underwriters of their over-allotment option in the amount of 3,000,000 Units, at $10.00 per Unit, generati…

• Following the closing of the initial public offering and the private placement, a total of $240,000,000 was placed in the trust account. The proceeds held in the trust account will be invested only in U.S. government treasury obligations with a maturity of 185 days or less or in money market funds m…

• The remaining proceeds from the initial public offering and the private placement are held outside the trust account, in the cash operating account amounting to $1,234,679 as of November 12, 2025. Such funds are being used primarily to enable us to identify a target and to negotiate and consummate o…

Text added vs the prior filing · source: 10-Q · 2026-05-12

• There was no change in our internal control over financial reporting that occurred during the fiscal quarter of 2026 covered by this Quarterly Report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Text removed vs the prior filing · source: 10-Q · 2025-12-16

• We do not expect that our disclosure controls and procedures will prevent all errors and all instances of fraud. Disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and proc…

• There was no change in our internal control over financial reporting that occurred during the fiscal quarter of 2025 covered by this Quarterly Report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.